A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial-Reference-Cited by-同舟云学术

A Study of Pazopanib Safety and Efficacy in Patients With Advanced Clear Cell Renal Cell Carcinoma and ECOG Performance Status 2 (Pazo2): An Open label, Multicentre, Single Arm, Phase II Trial

Published:2022-10 Issue:5 Volume:20 Page:473-481
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Zarkar Anjali,Pirrie Sarah^ORCID,Stubbs Clive^ORCID,Hodgkins Anne-Marie,Farrugia David^ORCID,Fife Kathryn,MacDonald-Smith Carey,Vasudev Naveen,Porfiri Emilio

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

2. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial;Sternberg;J Clin Oncol,2010

3. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial;Choueiri;J Clin Oncol,2017

4. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial;Motzer;J Clin Oncol,2013

5. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma;Future Oncology;2023-07-05

2. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer;Expert Review of Precision Medicine and Drug Development;2022-01-02